Phase I STTR grant supporting ProFine(R) study

MetCure received a $160,996 Phase I Small Business Technology Transfer (STTR) grant from the National Cancer Institute. This project is to investigate the efficacy of a novel nutraceutical agent ProFine in enhancing standard prostate cancer therapy.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s